Helix Pharma (Private) Limited: Validation Protocol
Helix Pharma (Private) Limited: Validation Protocol
Helix Pharma (Private) Limited: Validation Protocol
VALIDATION PROTOCOL
Document # VP/PRD/EQP-DQ-046
TITLE: Issue # 01
Effective Date 26-02-2020
DESIGN QUALIFICATION OF PASS BOX Review Date 26-02-2024
Supersede # 00
Page 1 of 4
PREPARED BY: REVIEWED BY: APPROVED BY:
TABLE OF CONTENTS
Sectio
Description Page No.
n
1.0 Objectives 2
2.0 Scope 2
3.0 Responsibilities 2
4.0 Equipment details 2
5.0 List of team members 2
6.0 Design qualification pre-requisites 2
7.0 Equipment design and principle of working 3
8.0 Design qualification specification 3-4
9.0 Deficiency or Corrective action report 4
10.0 Conclusion & summary 4
HELIX PHARMA (PRIVATE) LIMITED
VALIDATION PROTOCOL
Document # VP/PRD/EQP-DQ-046
TITLE: Issue # 01
Effective Date 26-02-2020
DESIGN QUALIFICATION OF PASS BOX Review Date 26-02-2024
Supersede # 00
Page 2 of 4
PREPARED BY: REVIEWED BY: APPROVED BY:
1.0 OBJECTIVE:
Purpose of design qualification is to ensure there is documented verification that the
proposed design is suitable for the intended purpose.
2.0 SCOPE:
This design qualification protocol is applicable to pass boxes in sterile area.
3.0 RESPONSIBLITIES:
3.1 QA responsible for generating the DQ protocol.
3.2 QA, QC, Production, Engineering are responsible for reviewing the protocol.
3.3 Director RA & QA responsible for approval of protocol.
Vendor Compliance
S. No. Parameters URS
Specification status
1 Size (width x depth
x height) internal
2 Size (width x depth
x height) external
3 Material of
construction
4 Pre-filter
5 HEPA Filter
6 Quantity
7 UV light
8 Quantity
9 On/off switch for
blower
HELIX PHARMA (PRIVATE) LIMITED
VALIDATION PROTOCOL
Document # VP/PRD/EQP-DQ-046
TITLE: Issue # 01
Effective Date 26-02-2020
DESIGN QUALIFICATION OF PASS BOX Review Date 26-02-2024
Supersede # 00
Page 4 of 4
PREPARED BY: REVIEWED BY: APPROVED BY:
Designation: Date:
Designation: Date: